Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

• Status: Withdrawn
• Trial end date: 1969-12-31

Summary

The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.

• Phase: Phase 1

Details

• Lead Sponsor: Vitreous -Retina- Macula Consultants of New York
• Collaborator: Genentech, Inc.
• Treatments: Imatinib Mesylate; Ranibizumab